Thursday, December 13, 2018

Esperion initiated at Goldman Sachs


Esperion initiated with a Sell at Goldman Sachs. Goldman Sachs analyst Paul Choi started Esperion Therapeutics with a Sell rating and $45 price target.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.